US64125C1099 - Common Stock - After market: 108.25 0 (0%)
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.
Investors are taking profits on this red-hot stock this week.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results...
Sharp Tesla price cuts and some notable earnings were in focus.
Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.
Voyager Therapeutics (VYGR) added ~29% pre-market Monday announcing a licensing agreement with Neurocrine Biosciences (NBIX) for multiple gene therapies. Read the full story here.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 41st Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Pacific Time on...
Neurocrine Biosciences (NBIX) said the U.S. FDA had accepted its supplemental new drug application for its treatment for Huntington's disease. Read more on the nod here.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and...
UnitedHealth is among medical stocks holding key support.
Neurocrine Biosciences (NBIX) announced that its investigational calcium channel blocker NBI-827104 failed in a Phase 2 trial in children with epileptic disorder. Read full story here.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that investigational...
SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, tod...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical...
Neurodegenerative disorders could mean big bucks for some biotechs.
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor...
A mixed jobs report and heavy earnings swung stocks.
SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA®...
SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, tod...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from...
The company raised its guidance for Ingrezza sales in 2022.
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $376 MillionINGREZZA® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1...